CombinatoRx Incorporated: Premium Company Profile

Publication Date	December 2007
Publisher	Datamonitor
Product Type	Databook
Pages	46
ISBN Number	not applicable
Product Code	DAT09417

Price

£265.00
approximately: $521 | €337

PRINT £265 ($521 | €337)

Order above formats by FAX

Summary

Introduction

CombinatoRx develops combinations of approved drugs to target multiple disease pathways to treat cancer, type 2 diabetes, rheumatoid arthritis, and other immuno-inflammatory diseases. CombinatoRx applies an innovative drug discovery approach of combination high throughput screening technology (cHTS) that can rapidly and reproducibly identify novel drugs.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

CombinatoRx is a biopharmaceutical company engaged in developing synergistic combinations of approved drugs for the treatment of immuno-inflammatory diseases, chronic pain, topical dermatoses, metabolic disease and oncology. It's product line is internally generated from its combination high throughput screening (cHTS) technology.

CombinatoRx's total revenues increased from $0.1 million in 2004 to $13 million in 2006. Prior to 2004, the company did not record revenues.

The table highlights CombinatoRx's absolute revenue growth of +$5 million with sales of $13 million in 2006 increasing to $18 million in 2010, growing at a CAGR of 8%.

Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content

Overview
Catalyst
- Summary
- Company Structure
- Company Overview and Key Facts
- Business Description
- History
- Locations and Subsidiaries
- Company Financials
- Stock Market Performance
- P&L
- Balance Sheet
- Cash Flow
- Business Segment Performance
- Products & Services
- Pipeline Products
- AC Forecast Product Sales
- Competitors and Strategic Business Relationships
- Key Competitors
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
- Overview
- Discovery and Product Development
- Manufacturing
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- List of Key Employees
- Key Employee Biographies
- Financial and Operational Overview
- Financial and Operational Overview
Appendix
- Ask the analyst
- Datamonitor consulting
- Disclaimer
- Figure 1: CombinatoRx - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 1: CombinatoRx - Key Facts
- Table 2: CombinatoRx - Locations and Subsidiaries
- Table 3: CombinatoRx - Year-End Share Price and Market Capitalization, 2002-2006 ($)
- Table 4: CombinatoRx - Key Events Impacting Share Price Performance
- Table 5: CombinatoRx - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Table 6: CombinatoRx - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
- Table 7: CombinatoRx - Balance Sheet, 2002-2006 ($ Mn)
- Table 8: CombinatoRx - Cash Flow, 2002-2006 ($ Mn)
- Table 9: CombinatoRx - Revenue Breakdown, 2002-2006 ($ Mn)
- Table 10: CombinatoRx - in-house Pipeline Products
- Table 11: CombinatoRx- Key Strategic Revenues, 2006-2010 ($ Mn)
- Table 12: CombinatoRx - Key Competitors
- Table 13: CombinatoRx - Key Clients
- Table 14: CombinatoRx - Key Shareholders
- Table 15: CombinatoRx - SWOT Analysis Summary
- Table 16: CombinatoRx - Value Chain Analysis
- Table 17: CombinatoRx - Scorecard
- Table 18: CombinatoRx - Key Employees
- Table 19: CombinatoRx - Financial and Operational Overview